Viking Therapeutics prices upsized $500M offering of common stock and convertible senior notes

Viking Therapeutics priced an upsized $500M offering of common stock and convertible senior notes, up from the $200M common stock and $200M convertible notes it had announced. Proceeds will fund clinical development of VK2735 and VK3019 and general corporate purposes.

Detected & updated continuously · Source: Nebula